Amivantamab Plus Chemotherapy Shows Promising Long-Term Responses in Colorectal Cancer

Novartis Expands US Radioligand Manufacturing With $23 Billion Investment in Florida

Rewiring RNA: Antisense RNA Therapy Exposes a New Weakness in Pancreatic Cancer

TRBC2-Specific ADC Shows Robust Efficacy in T-Cell Lymphomas and Leukemias

Engineered Oncolytic Virus Reprograms Immunity and Extends Survival in Brain Cancer

Platinum-Free PADCEV Plus Pembrolizumab Improves Survival in MI Bladder Cancer

FDA Approves First Subcutaneous Amivantamab Plus Lazertinib for EGFR+ Lung Cancer

FDA Approves T-DXd Plus Pertuzumab as a First-Line Standard in HER2+ Breast Cancer

Less Toxic, More Effective: RW Evidence Supports Reduced Immunotherapy Dose in Melanoma

FDA Approves AKEEGA for BRCA2+ Prostate Cancer as the First Precision Therapy

Artificial Intelligence Detects Pancreatic Cancer More Accurately Than Radiologists

Preoperative Radiation May Improve Immune Response in HR+ HER2- Breast Cancer

Giredestrant Cuts Risk of Invasive Recurrence by 30% in Early ER+ Breast Cancer

Tucatinib Combination Cuts Progression Risk by 36% in HER2+ Metastatic Breast Cancer

GSK’s ADC Risvutatug Rezetecan Earns FDA Orphan Drug Status for Small Cell Lung Cancer

Teclistamab plus Daratumumab Achieves an 83% Risk Reduction in R/R Multiple Myeloma

CAR T Anito cel Delivers Deep, Durable Responses in R&R Multiple Myeloma

Ribociclib Maintains Long-Term Disease Control in HR+ HER2 Metastatic Breast Cancer

Lunsumio Combo Deliver High Response Rates in Follicular and Large B-Cell Lymphomas

Colibactin’s Molecular Blueprint Exposes How a Gut Microbial Toxin Triggers Colorectal Cancer

Enozertinib Shows Strong Systemic and CNS Activity in EGFR Exon 20+ NSC Lung Cancer

Blood-Based cfDNA Test Demonstrates Potential for Detecting Lung Cancer in Nonsmokers

Nanotherapy Reprograms Glioblastoma Immunity Through Nose-to-Brain Delivery

Lung Organoids Offer a Revolutionary Path to Transform Drug Testing and Cancer Therapies

FDA Approves Durvalumab as First Perioperative Immunotherapy for GEJ Cancers

FDA Approves Keytruda–Padcev Combo as First Perioperative Treatment for Bladder Cancer

Sevabertinib Wins FDA Approval with Strong Responses in HER2+ NSC Lung Cancer

FDA Approves Epcoritamab-bysp as the First Bispecific Antibody for Follicular Lymphoma

FDA Approves Ziftomenib as a New Targeted Option for NPM1+ Acute Myeloid Leukemia

Novartis Invests $23 Billion to Boost Radioligand Manufacturing Capacity in Carlsbad